2019 -- H 5434 SUBSTITUTE A | |
======== | |
LC001373/SUB A | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2019 | |
____________ | |
A N A C T | |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT | |
| |
Introduced By: Representatives Amore, Serodio, Ruggiero, and Kazarian | |
Date Introduced: February 14, 2019 | |
Referred To: House Health, Education & Welfare | |
(by request) | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Sections 5-37.4-2 and 5-37.4-3 of the General Laws in Chapter 5-37.4 |
2 | entitled "Intractable Pain Treatment" are hereby amended to read as follows: |
3 | 5-37.4-2. Definitions. |
4 | For purposes of this chapter: |
5 | (1) "Chronic intractable pain" means pain that is: excruciating; constant; incurable, and of |
6 | such severity that it dominates virtually every conscious moment; produces mental and physical |
7 | debilitation; and may produce a desire to commit suicide for the sole purpose of stopping the |
8 | pain. A diagnosis of chronic intractable pain made by a physician licensed in any of the states or |
9 | the District of Columbia and supported by written documentation of the diagnosis by the treating |
10 | physician shall constitute proof that the patient suffers from chronic intractable pain. |
11 | (1)(2) "Director" means the director of the department of health of the state of Rhode |
12 | Island. |
13 | (2)(3) "Intractable pain" means a pain state that persists beyond the usual course of an |
14 | acute disease or healing of an injury or results from a chronic disease or condition that causes |
15 | continuous or intermittent pain over a period of months or years. Unless the context clearly |
16 | indicates otherwise, the term intractable pain includes chronic intractable pain. |
17 | (3)(4) "Practitioner" means health care professionals licensed to distribute, dispense, or |
18 | administer controlled substances in the course of professional practice as defined in § 21-28- |
19 | 1.02(41). |
| |
1 | (4)(5) "Therapeutic purpose" means the use of controlled substances for the treatment of |
2 | pain in appropriate doses as indicated by the patient's medical record. Any other use is |
3 | nontherapeutic. |
4 | 5-37.4-3. Controlled substances. |
5 | (a) A practitioner may prescribe, administer, or dispense controlled substances not |
6 | prohibited by law for a therapeutic purpose to a person diagnosed and treated by a practitioner for |
7 | a condition resulting in intractable pain, if this diagnosis and treatment has been documented in |
8 | the practitioner's medical records. No practitioner shall be subject to disciplinary action by the |
9 | board solely for prescribing, administering, or dispensing controlled substances when prescribed, |
10 | administered, or dispensed for a therapeutic purpose for a person diagnosed and treated by a |
11 | practitioner for a condition resulting in intractable pain, if this diagnosis and treatment has been |
12 | documented in the practitioner's medical records. |
13 | (b) The provisions of subsection (a) of this section do not apply to those persons being |
14 | treated by a practitioner for chemical dependency because of their use of controlled substances |
15 | not related to the therapeutic purposes of treatment of intractable pain. |
16 | (c) The provisions of subsection (a) of this section provide no authority to a practitioner |
17 | to prescribe, administer, or dispense controlled substances to a person the practitioner knows or |
18 | should know to be using the prescribed, administered, or dispensed controlled substance non- |
19 | therapeutically. |
20 | (d) Drug dependency or the possibility of drug dependency in and of itself is not a reason |
21 | to withhold or prohibit prescribing, administering, or dispensing controlled substances for the |
22 | therapeutic purpose of treatment of a person for intractable pain, nor shall dependency relating |
23 | solely to this prescribing, administering, or dispensing subject a practitioner to disciplinary action |
24 | by the director. |
25 | (e) Practitioners shall not refuse treatment under this chapter for the sole reason that a |
26 | patient requires intensive treatment. |
27 | (f) Pharmacists shall not refuse to refill a prescription related to the diagnosis of |
28 | intractable or chronic intractable pain. |
29 | (g) In coordination with §§ 21-28-3.20 and 21-28-3.20.1, the director of health shall |
30 | promulgate rules and regulations necessary to effectuate the purpose of this chapter and ensure |
31 | that patients with intractable or chronic intractable pain are treated with dignity and not unduly |
32 | denied the medications needed to treat their conditions. |
33 | (e)(h) Nothing in this section shall deny the right of the director to deny, revoke, or |
34 | suspend the license of any practitioner or discipline any practitioner who: |
| LC001373/SUB A - Page 2 of 7 |
1 | (1) Prescribes, administers, or dispenses a controlled substance that is nontherapeutic in |
2 | nature or nontherapeutic in the manner in which it is prescribed, administered, or dispensed, or |
3 | fails to keep complete and accurate on-going records of the diagnosis and treatment plan; |
4 | (2) Fails to keep complete and accurate records of controlled substances received, |
5 | prescribed, dispensed and administered, and disposal of drugs as required by law or of controlled |
6 | substances scheduled in the Comprehensive Drug Abuse Prevention and Control Act of 1970, 21 |
7 | U.S.C. § 801, et seq. A practitioner shall keep records of controlled substances received, |
8 | prescribed, dispensed and administered, and disposal of these drugs shall include the date of |
9 | receipt of the drugs, the sale or disposal of the drugs by the practitioner, the name and address of |
10 | the person receiving the drugs, and the reason for the disposal or the dispensing of the drugs to |
11 | the person; |
12 | (3) Writes false or fictitious prescriptions for controlled substances as prohibited by law, |
13 | or for controlled substances scheduled in the Comprehensive Drug Abuse Prevention and Control |
14 | Act of 1970, 21 U.S.C § 801, et seq.; or |
15 | (4) Prescribes, administers, or dispenses in a manner which is inconsistent with |
16 | provisions of the law, or the Comprehensive Drug Abuse Prevention and Control Act of 1970, 21 |
17 | U.S.C. § 801, et seq., any controlled substance. |
18 | (f)(i) A practitioner may administer a controlled substance prescribed by a practitioner |
19 | and not prohibited by law for a therapeutic purpose to a person diagnosed and treated by a |
20 | practitioner for a condition resulting in intractable pain, if this diagnosis and treatment has been |
21 | documented in the practitioner's medical records. No practitioner shall be subject to disciplinary |
22 | action by the director solely for administering controlled substances when prescribed or dispensed |
23 | for a therapeutic purpose for a person diagnosed and treated by a practitioner for a condition |
24 | resulting in intractable pain, if this diagnosis and treatment has been documented in the |
25 | practitioner's medical records of the patient. |
26 | SECTION 2. Section 21-28-3.20 of the General Laws in Chapter 21-28 entitled "Uniform |
27 | Controlled Substances Act" is hereby amended to read as follows: |
28 | 21-28-3.20. Authority of practitioner to prescribe, administer, and dispense. |
29 | (a) A practitioner, in good faith and in the course of his or her professional practice only, |
30 | may prescribe, administer, and dispense controlled substances, or he or she may cause the |
31 | controlled substances to be administered by a nurse or intern under his or her direction and |
32 | supervision. |
33 | (b) The prescription-monitoring program shall be reviewed prior to starting any opioid. A |
34 | prescribing practitioner, or designee as authorized by § 21-28-3.32(a)(3), shall review the |
| LC001373/SUB A - Page 3 of 7 |
1 | prescription-monitoring program prior to refilling or initiating opioid therapy with an intrathecal |
2 | pump. For patients the prescribing practitioner is maintaining on continuous opioid therapy for |
3 | pain for three (3) months or longer, the prescribing practitioner shall review information from the |
4 | prescription-monitoring program at least every three (3) months. Documentation of that review |
5 | shall be noted in the patient's medical record. |
6 | (c) The director of health shall develop regulations for prescribing practitioners on |
7 | appropriate limits of opioid use in acute pain management. Initial prescriptions of opioids for |
8 | acute pain management of outpatient adults shall not exceed thirty (30) morphine milligram |
9 | equivalents (MMEs) total daily dose per day for a maximum total of twenty (20) doses, and, for |
10 | pediatric patients, the appropriate opioid dosage maximum per the department of health. |
11 | (d) For the purposes of this section, acute pain management shall not include chronic pain |
12 | management, pain associated with a cancer diagnosis, palliative or nursing home care, intractable |
13 | or chronic intractable pain, as provided in chapter 37.4 of title 5, or other exception in accordance |
14 | with department of health regulations: |
15 | (e) Subsection (c) shall not apply to medications designed for the treatment of substance |
16 | abuse or opioid dependence. |
17 | (f) On or before September 1, 2018, the director of health shall develop, and make |
18 | available to health-care practitioners, information on best practices for co-prescribing opioid |
19 | antagonists to patients. The best practices information shall identify situations in which co- |
20 | prescribing an opioid antagonist may be appropriate, including, but not limited to: |
21 | (1) In conjunction with a prescription for an opioid medication, under circumstances in |
22 | which the health-care practitioner determines the patient is at an elevated risk for an opioid drug |
23 | overdose; |
24 | (2) In conjunction with medications prescribed pursuant to a course of medication |
25 | therapy management for the treatment of a substance use disorder involving opioids; or |
26 | (3) Under any other circumstances in which a health-care practitioner identifies a patient |
27 | as being at an elevated risk for an opioid drug overdose. |
28 | (g) The best practices information developed pursuant to subsection (f) of this section |
29 | shall include guidelines for determining when a patient is at an elevated risk for an opioid drug |
30 | overdose, including, but not limited to, situations in which the patient: |
31 | (1) Meets the criteria provided in the opioid overdose toolkit published by the federal |
32 | substance abuse and mental health service administration; |
33 | (2) Is receiving high-dose, extended-release, or long-acting opioid medications; |
34 | (3) Has a documented history of an alcohol or substance use disorder, or a mental health |
| LC001373/SUB A - Page 4 of 7 |
1 | disorder; |
2 | (4) Has a respiratory ailment or other co-morbidity that may be exacerbated by the use of |
3 | opioid medications; |
4 | (5) Has a known history of intravenous drug use or misuse of prescription opioids; |
5 | (6) Has received emergency medical care or been hospitalized for an opioid overdose; or |
6 | (7) Uses opioids with antidepressants, benzodiazepines, alcohol, or other drugs. |
7 | (h) On or before September 1, 2018, the director of health and the secretary of the |
8 | executive office of health and human services shall develop strategies that include: |
9 | (1) Allowing practitioners in non-pharmacy settings to prescribe and dispense opioid |
10 | antagonists; and |
11 | (2) Ensuring that opioid antagonists that are distributed in a non-pharmacy setting are |
12 | eligible for reimbursement from any health insurance carrier, as defined under chapters 18, 19, |
13 | 20, and 41 of title 27, and the Rhode Island medical assistance program, as defined under chapter |
14 | 7.2 of title 42. |
15 | SECTION 3. Chapter 21-28 of the General Laws entitled "Uniform Controlled |
16 | Substances Act" is hereby amended by adding thereto the following section: |
17 | 21-28-3.20.1. Authority of practitioner to prescribe, administer, and dispense -- |
18 | Cancer, palliative care and chronic intractable pain. |
19 | (a) A practitioner, in good faith and in the course of his or her professional practice |
20 | managing pain associated with a cancer diagnosis, palliative or nursing home care, intractable or |
21 | chronic intractable pain as provided in chapter 37.4 of title 5, or other condition allowed by |
22 | department of health regulations pursuant to the exception in § 21-28-3.20(d), may prescribe, |
23 | administer, and dispense controlled substances, or he or she may cause the controlled substances |
24 | to be administered by a nurse or intern under his or her direction and supervision without regard |
25 | to the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. |
26 | (b) Practitioners, in the course of their professional practice, shall not refuse treatment to |
27 | patients covered under this section for the sole reason that these patients require intensive |
28 | treatment. |
29 | (c) Pharmacists, upon receiving the proper documentation that a person suffers from a |
30 | condition set forth in this section, shall not refuse to fill a prescription related to the diagnosis. |
31 | Documentation related to the filling of a prescription under this subsection shall only be required |
32 | by the pharmacist upon the initial filling of the prescription. |
33 | (d) The director of health shall promulgate those rules and regulations necessary to |
34 | effectuate the provisions of this section and ensure that rules governing pain management |
| LC001373/SUB A - Page 5 of 7 |
1 | associated with a cancer diagnosis, palliative or nursing home care, intractable or chronic |
2 | intractable pain as provided in chapter 37.4 of title 5, or other condition allowed by department of |
3 | health regulations pursuant to the exception created in § 21-28-3.20(d), shall: |
4 | (1) Take into consideration the individualized needs of patients covered by this section; |
5 | (2) Make provisions for practitioners, acting in good faith, and in the course of their |
6 | profession, and managing pain associated with their patients' illness to use their best judgment |
7 | notwithstanding any statute, rule or regulation to the contrary; and |
8 | (3) Ensure that patients covered by this section are treated with dignity and not unduly |
9 | denied the medications needed to treat their conditions. |
10 | SECTION 4. This act shall take effect upon passage. |
======== | |
LC001373/SUB A | |
======== | |
| LC001373/SUB A - Page 6 of 7 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT | |
*** | |
1 | This act would exclude chronic intractable pain from the definition of "acute pain |
2 | management", for purposes of prescribing, administering and dispensing controlled substances by |
3 | a practitioner. The act would prescribe new guidelines for the treatment of "chronic intractable |
4 | pain" based upon the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. |
5 | This act would take effect upon passage. |
======== | |
LC001373/SUB A | |
======== | |
| LC001373/SUB A - Page 7 of 7 |